4.7 Article

Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity

Journal

COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
Volume 19, Issue -, Pages 1998-2017

Publisher

ELSEVIER
DOI: 10.1016/j.csbj.2021.04.014

Keywords

Coronavirus; COVID-19; Drug repurposing; Network analysis; Docking; Polypharmacology; Molecular dynamics

Funding

  1. Dept. of Biotechnology, Govt. of India [BT/PR5430/MED/29/566/2012]
  2. DBT
  3. University Grant Commission (UGC)
  4. DST [SR/WOS-A/CS-129/2016]
  5. DBT-Wellcome trust India alliance [IA/I/15/1/501826]

Ask authors/readers for more resources

This study utilized bioinformatics techniques to screen FDA approved drugs against SARS-CoV2 proteins and identified 74 molecules that can bind to various SARS-CoV2 and human host proteins, with some showing good activity against SARS-CoV2. Experimental validation using vero E6 cells infected with SARS-CoV2 virus showed promising results, suggesting that these studies may help in developing new therapeutic options for COVID-19 treatment.
The SARS-CoV2 is a highly contagious pathogen that causes COVID-19 disease. It has affected millions of people globally with an average lethality of similar to 3%. There is an urgent need of drugs for the treatment of COVID-19. In the current studies, we have used bioinformatics techniques to screen the FDA approved drugs against nine SARS-CoV2 proteins to identify drugs for repurposing. Additionally, we analyzed if the identified molecules can also affect the human proteins whose expression in lung changed during SARS-CoV2 infection. Targeting such genes may also be a beneficial strategy to curb disease manifestation. We have identified 74 molecules that can bind to various SARS-CoV2 and human host proteins. We experimentally validated our in-silico predictions using vero E6 cells infected with SARS-CoV2 virus. Interestingly, many of our predicted molecules viz. capreomycin, celecoxib, mefloquine, montelukast, and nebivolol showed good activity (IC50) against SARS-CoV2. We hope that these studies may help in the development of new therapeutic options for the treatment of COVID-19. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available